Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
13d
Viking Therapeutics Inc (VKTX) showcases promising clinical advancements and robust cash reserves, despite increased expenses ...
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $71.75 which represents a decrease of $-1.60 or -2.18% from the prior close of $73.35. The stock opened at $71 and ...
Q3 2024 Earnings Call Transcript October 23, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Viking Therapeutics Inc (VKTX), a clinical-stage biopharmaceutical company, recently reported its financial results for the third quarter ending September 30, 2024. This quarter has been pivotal for ...
On Friday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $78.03 which represents a slight increase of $4.81 or 6.57% from the prior close of $73.22. The stock opened at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback